These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38491747)

  • 21. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.
    Grundman M; Morgan R; Lickliter JD; Schneider LS; DeKosky S; Izzo NJ; Guttendorf R; Higgin M; Pribyl J; Mozzoni K; Safferstein H; Catalano SM
    Alzheimers Dement (N Y); 2019; 5():20-26. PubMed ID: 30723776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging amyloid and tau targeting treatments for Alzheimer's disease.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):697-711. PubMed ID: 28490214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies.
    Broadstock M; Ballard C; Corbett A
    Expert Opin Pharmacother; 2014 Sep; 15(13):1797-810. PubMed ID: 24992196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Major Hypotheses of Alzheimer's Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment.
    Cáceres C; Heusser B; Garnham A; Moczko E
    Cells; 2023 Nov; 12(23):. PubMed ID: 38067098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
    Lopez Lopez C; Tariot PN; Caputo A; Langbaum JB; Liu F; Riviere ME; Langlois C; Rouzade-Dominguez ML; Zalesak M; Hendrix S; Thomas RG; Viglietta V; Lenz R; Ryan JM; Graf A; Reiman EM
    Alzheimers Dement (N Y); 2019; 5():216-227. PubMed ID: 31211217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profiling lecanemab as a treatment option for Alzheimer's disease.
    Schiller ER; Silverglate BD; Grossberg GT
    Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
    Teng E; Manser PT; Shah M; Pickthorn K; Hu N; Djakovic S; Swendsen H; Blendstrup M; Faccin G; Ostrowitzki S; Sink KM
    J Prev Alzheimers Dis; 2023; 10(1):41-49. PubMed ID: 36641609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease.
    Jojo GM; Kuppusamy G
    J Clin Pharm Ther; 2019 Jun; 44(3):337-348. PubMed ID: 30738020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.
    Kurkinen M
    Adv Clin Exp Med; 2023 Sep; 32(9):943-947. PubMed ID: 37676096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WITHDRAWN: Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterizing Alzheimer's disease through metabolomics and investigating anti-Alzheimer's disease effects of natural products.
    Yi L; Liu W; Wang Z; Ren D; Peng W
    Ann N Y Acad Sci; 2017 Jun; 1398(1):130-141. PubMed ID: 28632966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Landscape of Phase 2 Trials in Alzheimer's Disease": Perspective on Adaptive Trials.
    Cummings J
    J Alzheimers Dis; 2024; 98(3):859-861. PubMed ID: 38517794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.
    Zhang J
    Inflamm Res; 2023 Sep; 72(9):1873-1876. PubMed ID: 37682322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Alzheimer's Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer's Disease.
    Lopez Lopez C; Caputo A; Liu F; Riviere ME; Rouzade-Dominguez ML; Thomas RG; Langbaum JB; Lenz R; Reiman EM; Graf A; Tariot PN
    J Prev Alzheimers Dis; 2017; 4(4):242-246. PubMed ID: 29181489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity.
    Beierlein JM; McNamee LM; Walsh MJ; Ledley FD
    Clin Ther; 2015 Aug; 37(8):1643-51.e3. PubMed ID: 26243074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer's Disease.
    Padhi D; Govindaraju T
    J Med Chem; 2022 May; 65(10):7088-7105. PubMed ID: 35559617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unleashing the Power of Bayesian Re-Analysis: Enhancing Insights into Lecanemab (Clarity AD) Phase III Trial Through Informed t-Test.
    Costa T; Premi E; Liloia D; Cauda F; Manuello J
    J Alzheimers Dis; 2023; 95(3):1059-1065. PubMed ID: 37638445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.